CinDome Pharma Announces Completion of Enrollment in the envisionGI Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Idiopathic Gastroparesis Read More March 17, 2026
CinDome Pharma Announces Enrollment Completion in the envision3D Phase 2 Clinical Trial of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis Read More September 3, 2025
CinDome Pharma Announces First Patient Dosed in Clinical Trial of Deudomperidone (CIN-102) Read More June 4, 2025
CinRx Portfolio Company CinDome Pharma Presents Encouraging Data on Deudomperidone (CIN-102) at 2023 Digestive Disease Week® Conference Read More May 8, 2023
CinRx’s CinDome Pharma to Present a Poster on Deudomperidone (CIN-102) at 2023 Digestive Disease Week® Conference Read More May 2, 2023
CinRx Pharma Announces First Participant Dosed in CinDome’s Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis Read More April 27, 2023
CinDome Pharma announces successful completion of thorough QT study of CIN- 102 Read More January 25, 2022
CinDome Pharma Announces Start of Phase 2 Trial of Deuterated Domperidone (CIN-102) Read More September 19, 2019
